BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 27927959)

  • 1. Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.
    Liu W; Zhao L; Blackman B; Parmar M; Wong MY; Woo T; Yu F; Chiuchiolo MJ; Sondhi D; Kaminsky SM; Crystal RG; Paul SM
    J Neurosci; 2016 Dec; 36(49):12425-12435. PubMed ID: 27927959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.
    Ittner A; Bertz J; Suh LS; Stevens CH; Götz J; Ittner LM
    J Neurochem; 2015 Jan; 132(1):135-45. PubMed ID: 25041093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.
    Boutajangout A; Ingadottir J; Davies P; Sigurdsson EM
    J Neurochem; 2011 Aug; 118(4):658-67. PubMed ID: 21644996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity.
    d'Abramo C; Acker CM; Jimenez HT; Davies P
    PLoS One; 2013; 8(4):e62402. PubMed ID: 23638068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.
    Sankaranarayanan S; Barten DM; Vana L; Devidze N; Yang L; Cadelina G; Hoque N; DeCarr L; Keenan S; Lin A; Cao Y; Snyder B; Zhang B; Nitla M; Hirschfeld G; Barrezueta N; Polson C; Wes P; Rangan VS; Cacace A; Albright CF; Meredith J; Trojanowski JQ; Lee VM; Brunden KR; Ahlijanian M
    PLoS One; 2015; 10(5):e0125614. PubMed ID: 25933020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau passive immunization blocks seeding and spread of Alzheimer hyperphosphorylated Tau-induced pathology in 3 × Tg-AD mice.
    Dai CL; Hu W; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2018 Jan; 10(1):13. PubMed ID: 29386065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice.
    Vitale F; Giliberto L; Ruiz S; Steslow K; Marambaud P; d'Abramo C
    Acta Neuropathol Commun; 2018 Aug; 6(1):82. PubMed ID: 30134961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies.
    Lathuilière A; Laversenne V; Astolfo A; Kopetzki E; Jacobsen H; Stampanoni M; Bohrmann B; Schneider BL; Aebischer P
    Brain; 2016 May; 139(Pt 5):1587-604. PubMed ID: 26956423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.
    Ising C; Gallardo G; Leyns CEG; Wong CH; Jiang H; Stewart F; Koscal LJ; Roh J; Robinson GO; Remolina Serrano J; Holtzman DM
    J Exp Med; 2017 May; 214(5):1227-1238. PubMed ID: 28416651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with Sarkosyl insoluble PHF-tau decrease neurofibrillary tangles formation in aged tau transgenic mouse model: a pilot study.
    Ando K; Kabova A; Stygelbout V; Leroy K; Heraud C; Frédérick C; Suain V; Yilmaz Z; Authelet M; Dedecker R; Potier MC; Duyckaerts C; Brion JP
    J Alzheimers Dis; 2014; 40 Suppl 1():S135-45. PubMed ID: 24614899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies.
    d'Abramo C; Acker CM; Jimenez H; Davies P
    PLoS One; 2015; 10(8):e0135774. PubMed ID: 26270821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral Delivery of Non-Mutated Human Truncated Tau to Neurons Recapitulates Key Features of Human Tauopathy in Wild-Type Mice.
    Vogels T; Vargová G; Brezováková V; Quint WH; Hromádka T
    J Alzheimers Dis; 2020; 77(2):551-568. PubMed ID: 32675411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model.
    Nisbet RM; Van der Jeugd A; Leinenga G; Evans HT; Janowicz PW; Götz J
    Brain; 2017 May; 140(5):1220-1230. PubMed ID: 28379300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.
    Chai X; Wu S; Murray TK; Kinley R; Cella CV; Sims H; Buckner N; Hanmer J; Davies P; O'Neill MJ; Hutton ML; Citron M
    J Biol Chem; 2011 Sep; 286(39):34457-67. PubMed ID: 21841002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice.
    Jaworski T; Dewachter I; Lechat B; Croes S; Termont A; Demedts D; Borghgraef P; Devijver H; Filipkowski RK; Kaczmarek L; Kügler S; Van Leuven F
    PLoS One; 2009 Oct; 4(10):e7280. PubMed ID: 19794916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B core VLP-based mis-disordered tau vaccine elicits strong immune response and alleviates cognitive deficits and neuropathology progression in Tau.P301S mouse model of Alzheimer's disease and frontotemporal dementia.
    Ji M; Xie XX; Liu DQ; Yu XL; Zhang Y; Zhang LX; Wang SW; Huang YR; Liu RT
    Alzheimers Res Ther; 2018 Jun; 10(1):55. PubMed ID: 29914543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau passive immunization inhibits not only tau but also Aβ pathology.
    Dai CL; Tung YC; Liu F; Gong CX; Iqbal K
    Alzheimers Res Ther; 2017 Jan; 9(1):1. PubMed ID: 28073379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
    Helboe L; Egebjerg J; Barkholt P; Volbracht C
    Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles.
    Castillo-Carranza DL; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Gerson JE; Singh G; Estes DM; Barrett AD; Dineley KT; Jackson GR; Kayed R
    J Neurosci; 2014 Mar; 34(12):4260-72. PubMed ID: 24647946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.